Communiqués cbdMD, Inc.

Actions

YCBD

US12482W4087

Produits pharmaceutiques

Marché Fermé - NYSE 22:00:00 28/08/2026			Varia. 5j.	Varia. 1 janv.
0,5000 ^USD	+0,58%		-1,75%	-62,96%

17/08	CbdMD, Inc. : Maxim neutre sur le dossier	ZM
13/08	Transcript : CbdMD, Inc., Q3 2026 Earnings Call, Aug 13, 2026

Communiqués

13/08	CbdMD Reports 20% Year-over-Year Revenue Growth for the Third Fiscal Quarter of 2026	PR
10/08	CbdMD, Inc. to Host Conference Call to Discuss June 30, 2026, Third Quarter Results	PR
03/08	CbdMD Applauds Proposed SENATE SPENDING BILL That Would Protect Access to Full-Spectrum CBD and Other Naturally Derived Hemp Products	PR
27/07	CbdMD Supports the Bipartisan Lawful Hemp Protection Act to Protect Consumers and Full-Spectrum CBD Access	AQ
24/07	CbdMD Supports the Bipartisan Lawful Hemp Protection Act to Protect Consumers and Full-Spectrum CBD Access	PR
14/07	CbdMD's Oasis Brand Partners with Mexcor to Launch Into South Carolina	PR
09/07	CbdMD's Bluebird Botanicals Announces Official Partnership With Denver Audubon to Support Bird Conservation	PR
07/07	CbdMD Sets a New Safety Standard for Broad Spectrum CBD With Self-Affirmed GRAS Determination	PR
01/07	Oasis Launches Hemp-Derived Mixer	PR
25/06	CbdMD Welcomes White House Call for Fair Treatment of Hemp-Derived Products	PR
16/06	CbdMD Appoints Wade Brown Chief Marketing Officer	PR
14/05	CbdMD Reports 19% Year-over-Year and 12% Sequential Revenue Growth; Bluebird Acquisition Integration and Medicare BEI Pathway Position Company for Continued Momentum	PR
12/05	CbdMD, Inc. to Host Conference Call to Discuss March 31, 2026, Second Quarter Results	PR
01/04	CbdMD Launches Clinical Healthcare Channel to Support First Federal Pathway for Hemp-Derived CBD in Medicare	PR
17/02	CbdMD Reports Sequential Revenue Growth, Improved Liquidity, and Strong Start to Fiscal 2026	PR
12/02	CbdMD, Inc. to Host Conference Call to Discuss December 31, 2025 First Quarter Results	PR
02/02	CbdMD's Herbal Oasis Expands into Louisiana with Morales Beverage Group Following Strong Texas Momentum	PR
29/01	CbdMD Strengthens Regulatory Science Platform to Support Emerging Regulatory Cannabinoid Evaluation Pathways	PR
20/01	CbdMD : Amendment to Annual Report (Form 10-K/A)	PU
14/01	CbdMD Announces Strategic Acquisition of Bluebird Botanicals	PR
19/12	CbdMD Reports Third Consecutive Year of Operating Improvement, Strengthens Balance Sheet, and Regains NYSE American Continued Listing Compliance	PR
19/12	CbdMD, Inc. Announces Closing of $2.25 Million Series C Preferred Stock Private Placement	PR
18/12	CbdMD, Inc. to Host Conference Call to Discuss September 30, 2025, Fourth Quarter and Fiscal Year 2025 Results	PR
08/12	CbdMD, Inc. Regains Compliance with NYSE American Listing Standards	PR
21/11	CbdMD Reports Preliminary Unaudited Fourth Quarter and Fiscal 2025 Results	PR